Short answer
Bio-rad Laboratories Inc (BIO) filed its Q3 2019 10-Q quarterly report on Nov 1, 2019 for the quarter ended Sep 30, 2019.
Bio-rad Laboratories Inc Q3 2019 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $560.6M, up 2.8% YoY from $545.1M
- Gross margin 54.8% vs 52.6% YoY, Clinical Diagnostics margin up 3.0 percentage points
- Best segment Life Science: $215.7M sales, up 4.5% YoY; Clinical Diagnostics $341.8M, up 2.4%
- Nine-month operating cash flow $298.1M vs $180.5M; cash and short-term investments $979.2M
- Headwinds: government healthcare spending constraints, trade disputes, regulation, and challenging European growth
Risk Factors
- Newly triggered financial-reporting risk: ASU 2016-02 adoption added material right-of-use assets and lease liabilities
- Most material market risk: Sartorius AG valuation decline reduced third-quarter 2019 net income by $390.6 million
- Regulatory risk: Brexit may add United Kingdom-European Union product, raw-material and personnel movement requirements
- Operational risk: ERP implementation issues delayed manufacturing and logistics, adversely affecting sales
- Financial risk: $439.6 million outstanding debt and $200.0 million revolving facility, with $0.2 million utilized for letters of credit
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Bio-rad Laboratories Inc quarterly reports
- Q2 2019 10-QFiled Aug 6, 2019
- Q1 2019 10-QFiled May 10, 2019
- Q3 2018 10-QFiled Nov 5, 2018
- Q2 2018 10-QFiled Aug 9, 2018
- Q1 2018 10-QFiled May 10, 2018
- Q3 2017 10-QFiled Nov 9, 2017
- Q2 2017 10-QFiled Aug 7, 2017
- Q1 2017 10-QFiled May 9, 2017
- Q3 2016 10-QFiled Nov 2, 2016
- Q2 2016 10-QFiled Aug 5, 2016
- Q1 2016 10-QFiled May 6, 2016
- Q3 2015 10-QFiled Nov 5, 2015
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.